Last updated: 02/28/2025 16:00:12

A study of belantamab mafodotin to investigate safety, tolerability, pharmacokinetics, immunogenicity and clinical activity in participants with Relapsed/Refractory Multiple Myeloma (RRMM)

GSK study ID
208465
See study documents
Clinicaltrials.gov ID
NCT04177823
See results summary
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and clinical activity of the Antibody Drug Conjugate GSK2857916 in Chinese Participants with Relapsed/Refractory Multiple Myeloma Who Have Failed At Least Two Lines of Previous Treatment, Containing an alkylator, a Proteasome Inhibitor and an Immunomodulatory Agent
Trial description: Multiple myeloma (MM) is a neoplastic plasma cell disorder that is characterized by osteolytic bone lesions, anemia, hypercalcemia and renal failure. belantamab mafodotin was well tolerated in previous studies with at least one dose of belantamab mafodotin in heavily pre-treated participants with relapsed/refractory multiple myeloma (RRMM). This aim of the study is to explore safety, pharmacokinetics (PK), tolerability, immunogenicity and clinical activity of belantamab mafodotin monotherapy in Chinese participants with RRMM who have received at least 2 prior line of anti-myeloma therapy including an alkylator, a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD). This study will include two dose cohorts 2.5 milligram per kilogram (mg/kg) and 3.4 mg/kg. A maximum of 12 participants will be enrolled, 6 each for 2.5 mg/kg cohort and 3.4 mg/kg cohort based on 3+3 design. Participants will be treated until disease progression, intolerable toxicity, end of study or informed consent withdrawal.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:

Number of participants with Adverse events (AEs)

Timeframe: Up to 15 months

Number of participants with serious adverse events (SAEs)

Timeframe: Up to 15 months

Number of participants with dose limited toxicities (DLTs)

Timeframe: Day 1 to Day 21 (Cycle 1)

Secondary outcomes:

Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury)

Timeframe: Baseline and up to 15 months

Change from Baseline in temperature (degrees Celsius)

Timeframe: Baseline and up to 15 months

Change from Baseline in pulse rate (beats per minute)

Timeframe: Baseline and up to 15 months

Change from Baseline in hematology parameters: platelet count, absolute white blood cells (WBC), reticulocyte count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils count (Giga cells per Liter)

Timeframe: Baseline and up to 15 months

Change from Baseline in hematology parameter: Red Blood Cell (RBC) Count (Trillion cells per liter)

Timeframe: Baseline and up to 15 months

Change from Baseline in hematology parameter: Hematocrit (Proportion of red blood cells in blood)

Timeframe: Baseline and up to 15 months

Change from Baseline in hematology parameter: Mean Corpuscular Hemoglobin (MCH) (Picograms)

Timeframe: Baseline and up to 15 months

Change from Baseline in hematology parameter: Mean Corpuscular Volume (MCV) (Femtoliters)

Timeframe: Baseline and up to 15 months

Change from Baseline in hematology parameter: Hemoglobin, Mean Corpuscular Hemoglobin concentration (MCHC) (Grams per Liter)

Timeframe: Baseline and up to 15 months

Change from Baseline in chemistry parameters: Blood urea nitrogen (BUN), Creatinine, Glucose, Calcium, Sodium, Potassium, Phosphorous, Chloride, Magnesium, Uric Acid, Carbon dioxide (CO2), Total and direct bilirubin (Millimoles per Liter)

Timeframe: Baseline and up to 15 months

Change from Baseline in chemistry parameter: estimated glomerular filtration rate (eGFR) (milliliter per minute per 1.73 meter square)

Timeframe: Baseline and up to 15 months

Change from Baseline in chemistry parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine kinase, Gamma Glutamyl Transferase (GGT), Lactate dehydrogenase (LDH) (International units per Liter)

Timeframe: Baseline and up to 15 months

Change from Baseline in chemistry parameters: Albumin, Total Protein (grams per liter)

Timeframe: Baseline and up to 15 months

Change from Baseline in chemistry parameter: Albumin/creatinine ratio (ratio)

Timeframe: Baseline and up to 15 months

Change from Baseline in Urinalysis Parameter: Specific Gravity (Ratio)

Timeframe: Baseline and up to 15 months

Change from Baseline in Urinalysis Parameter: Urine potential of hydrogen (pH)

Timeframe: Baseline and up to 15 months

Change from Baseline in urinalysis parameter: Glucose and ketones (Millimole per liter)

Timeframe: Baseline and up to 15 months

Change from Baseline in urinalysis parameter: Protein (Grams per liter)

Timeframe: Baseline and up to 15 months

Change from Baseline in urinalysis parameter: blood (10^9 cells per liter)

Timeframe: Baseline and up to 15 months

Area under the plasma concentration-time curve from time zero to time t (AUC[0-t]) after single dose of belantamab mafodotin (antibody-drug conjugate (ADC))

Timeframe: Day 1 to Day 21 (Cycle 1)

AUC(0-t) after single dose of belantamab mafodotin (total antibody)

Timeframe: Day 1 to Day 21 (Cycle 1)

AUC(0-t) after single dose of belantamab mafodotin (cys- monomethyl auristatin-F [mcMMAF])

Timeframe: Day 1 to Day 21 (Cycle 1)

Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC[0-infinity]) after single dose of belantamab mafodotin (ADC)

Timeframe: Day 1 to Day 21 (Cycle 1)

AUC(0-infinity) after single dose of belantamab mafodotin (total antibody)

Timeframe: Day 1 to Day 21 (Cycle 1)

Maximum observed plasma concentration (Cmax) after single dose of belantamab mafodotin (ADC)

Timeframe: Day 1 to Day 21 (Cycle 1)

Cmax after single dose of belantamab mafodotin (total antibody)

Timeframe: Day 1 to Day 21 (Cycle 1)

Cmax after single dose of belantamab mafodotin (cys-mcMMAF)

Timeframe: Day 1 to Day 21 (Cycle 1)

Time to Cmax (tmax) after single dose of belantamab mafodotin (ADC)

Timeframe: Day 1 to Day 21 (Cycle 1)

tmax after single dose of belantamab mafodotin (total antibody)

Timeframe: Day 1 to Day 21 (Cycle 1)

tmax after single dose of belantamab mafodotin (cys-mcMMAF)

Timeframe: Day 1 to Day 21 (Cycle 1)

Last time point where the concentration is above the limit of quantification (tlast) after single dose of belantamab mafodotin (ADC)

Timeframe: Day 1 to Day 21 (Cycle 1)

tlast after single dose of belantamab mafodotin (total antibody)

Timeframe: Day 1 to Day 21 (Cycle 1)

Systemic clearance (CL) after single dose of belantamab mafodotin (ADC)

Timeframe: Day 1 to Day 21 (Cycle 1)

CL after single dose of belantamab mafodotin (total antibody)

Timeframe: Day 1 to Day 21 (Cycle 1)

Volume of distribution at steady state (Vss) after single dose of belantamab mafodotin (ADC)

Timeframe: Day 1 to Day 21 (Cycle 1)

Vss after single dose of belantamab mafodotin (total antibody)

Timeframe: Day 1 to Day 21 (Cycle 1)

Terminal phase elimination rate (Lambda Z) after single dose of belantamab mafodotin (ADC)

Timeframe: Day 1 to Day 21 (Cycle 1)

Lambda Z after single dose of belantamab mafodotin (total antibody)

Timeframe: Day 1 to Day 21 (Cycle 1)

Terminal phase half-life (t1/2) after single dose of belantamab mafodotin (ADC)

Timeframe: Day 1 to Day 21 (Cycle 1)

t1/2 after single dose of belantamab mafodotin (total antibody)

Timeframe: Day 1 to Day 21 (Cycle 1)

t1/2 after single dose of belantamab mafodotin (cys-mcMMAF)

Timeframe: Day 1 to Day 21 (Cycle 1)

Trough concentration (Ctrough) after repeat dose of belantamab mafodotin (ADC)

Timeframe: Day 1 and Up to 15 months

Ctrough after repeat dose of belantamab mafodotin (total antibody)

Timeframe: Day 1 and Up to 15 months

Ctrough after repeat dose of belantamab mafodotin (cys-mcMMAF)

Timeframe: Day 1 and Up to 15 months

Number of subjects with abnormal ocular findings

Timeframe: Up to 15 months

Percentage of participants with Objective Response Rate (ORR)

Timeframe: Up to 15 months

Number of participants with Anti-drug antibodies (ADAs) against belantamab mafodotin

Timeframe: Up to 15 months

Titers of ADAs against belantamab mafodotin

Timeframe: Up to 15 months

Interventions:
  • Drug: Belantamab mafodotin
    • Enrollment:
    6
    Primary completion date:
    2021-30-12
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Multiple Myeloma
    Product
    Not applicable
    Collaborators
    Not applicable
    Study date(s)
    December 2019 to December 2021
    Type
    Interventional
    Phase
    1

    Participation criteria

    Sex
    Female & Male
    Age
    18+ years
    Accepts healthy volunteers
    No
    • Provide signed written informed consent, which includes compliance with requirements and restrictions listed in the consent form.
    • Male or female, 18 years or older (at the time consent is obtained).
    • Systemic anti-myeloma therapy within less than 14 days, or plasmapheresis within 7 days prior to the first dose of study drug.
    • Symptomatic amyloidosis, active polyneuropathy,organomegaly, endocrinopathy, myeloma protein, and skin changes (POEMS) syndrome, active plasma cell leukemia at the time of screening.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Provide signed written informed consent, which includes compliance with requirements and restrictions listed in the consent form.
    • Male or female, 18 years or older (at the time consent is obtained).
    • Eastern Cooper Oncology Group (ECOG) performance status of 0-2.
    • Histological or cytologically confirmed diagnosis of MM as defined according to IMWG criteria and a) Has undergone stem cell transplant or transplant is considered not feasible by local assessment, b) Has failed at least 2 prior lines of anti-myeloma treatments, containing all of the following classes of drugs: alkylating agent, IMID and PI, c) In addition, eligible participant needs to be refractory to an IMiD (i.e.,lenalidomide or pomalidomide), and to a proteasome inhibitor (i.e., bortezomib, ixazomib or carfizomib) as defined by International Myeloma Working Group (IMWG) criteria, d) Participants who failed with cluster of differentiation38 (CD38) antibody (i.e., daratumumab) in previous clinical trials can also be considered to include if they meet the remainder of inclusion criteria in this protocol.
    • Has measurable disease with at least one of the following: a) Serum M-protein greater than or equal to 0.5 grams per deciliter (g/dL) (5 g/L) , b) Urine M-protein greater than or equal to 200 mg/24hour, c) Serum Free light chain (FLC) assay: Involved FLC level greater than or equal to10 mg/dL (greater than or equal to 100 mg/L) and an abnormal serum free light chain ratio (less than 0.26 or greater than 1.65)
    • Participants with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: a) Transplant was greater than 100 days prior to study enrolment, b) No active infection(s), c) Participant meets the remainder of the eligibility criteria outlined in this protocol.
    • Adequate organ system functions.
    • Female Participants: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) or is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of less than 1 percent per year), preferably with low user dependency, during the intervention period and for at least 80 days after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention. The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
    • Male Participants: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 140 days: Refrain from donating sperm, plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. or Must agree to use contraception/barrier as detailed below: Agree to use a male condom and female partner to use an additional highly effective contraceptive method with a failure rate of less than 1 percent per year as when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.
    • All prior treatment-related toxicities (defined by National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0 must be less than or equal to Grade 1 at the time of enrolment except for alopecia and Grade 2 peripheral neuropathy.
    Exclusion criteria:
    • Systemic anti-myeloma therapy within less than 14 days, or plasmapheresis within 7 days prior to the first dose of study drug.
    • Symptomatic amyloidosis, active polyneuropathy,organomegaly, endocrinopathy, myeloma protein, and skin changes (POEMS) syndrome, active plasma cell leukemia at the time of screening.
    • Prior allogeneic stem cell transplant (SCT).
    • Current corneal epithelial disease except mild punctate keratopathy.
    • Use of an investigational drug within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug. Prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs. Prior B-cell maturation antigen (BCMA) targeted therapy.
    • Evidence of active mucosal or internal bleeding.
    • Any major surgery within the last four weeks.
    • Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant’s safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfil criteria.
    • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant’s safety, obtaining informed consent or compliance to the study procedures.
    • Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
    • Malignancies other than disease under study are excluded, except for any other malignancy from which the participant has been disease-free for more than 2 years and, in the opinion of the principal investigators and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM).
    • Evidence of cardiovascular risk including any of the following: a) corrected QT internal Fridericia (QTcF) interval greater than equal to 480 milliseconds (msecs), b) Evidence of current clinically significant untreated arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block, c) History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three months of Screening, d) Class III or IV heart failure as defined by the New York Heart Association functional classification system, e) Uncontrolled severe hypertension, e.g. 170/110.
    • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin, or any of the components of the study intervention.
    • Pregnant or lactating female.
    • Active infection requiring antibiotic, antiviral, or antifungal treatment.
    • Known human immunodeficiency virus (HIV) infection.
    • Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb at screening or within 3 months prior to first dose of study intervention).
    • Positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Beijing, China, 100191
    Status
    Study Complete
    Contact us

    Study documents

    Protocol
    Available language(s): English
    Download document(s)
    Statistical analysis plan
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    Study complete
    Actual primary completion date
    2021-30-12
    Actual study completion date
    2021-30-12

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website